Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study with a combination of Hycamptin® (topotecan) and
erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent
ovarian cancer previously treated with chemotherapy drug Hycamptin® (topotecan). Up to 30
patients will be enrolled in this study.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health